MS 818

Drug Profile

MS 818

Latest Information Update: 07 Sep 2004

Price : $50

At a glance

  • Originator Nihon Schering
  • Class Anti-ischaemics; Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Peripheral nervous system diseases

Most Recent Events

  • 15 Jun 2004 Discontinued - Preclinical for Peripheral nervous system diseases in Japan (unspecified route)
  • 27 Jun 2001 No-Development-Reported for Peripheral nervous system diseases in Japan (Unknown route)
  • 06 Apr 2001 A study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top